Info

>3 log +

49 (55)b

25 (64)

Undetectable

39 (44)b

17 (44)

aNot available.

bTwo patients have missing data.

Abbreviation: CHR, complete hematologic response.

aNot available.

bTwo patients have missing data.

Abbreviation: CHR, complete hematologic response.

This phase II trial included 115 patients in 29 institutions. These patients received 800 mg imatinib/day and treatment dose was adjusted for >3 toxicity grades. The primary endpoint of the trial is molecular response at the first year. Sokal classification was predominantly low (73.1%) or intermediate (17.3%). Peripheral blood PCR and FISH were measured every three months in a central laboratory. Table 2 described the interim analysis of this trial with a high rate of CCyR at 12 months (85%) and a high rate of major molecular response at six months (55%) and 12 months (64%).

Was this article helpful?

0 0

Post a comment